UK Markets closed

Healthcare group Sanofi forms research deal with the company Exscientia

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
Sanofi logo is seen in Aramon
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • SNY
  • EXAI

PARIS (Reuters) - French healthcare company Sanofi, which has been under pressure to revive its drug pipeline after some setbacks in the COVID-19 vaccine race, announced on Friday a research deal with the company Exscientia to develop new medicines.

The two companies said they would work on developing an artificial-intelligence (AI) driven pipeline of new products in areas such as oncology and immunology.

Exscientia will also receive an upfront cash payment of $100 million with the potential of $5.2 billion in total milestones plus tiered royalties, as part of the deal with Sanofi.

(Reporting by Sudip Kar-Gupta; Editing by Kim Coghill)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting